All In Biotech

NDA 022090 · Bayer Hlthcare

Eovist

Gadoxetate Disodium · Intravenous

Novel

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jul 3, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

2 Phase 3, 2 recruiting

FAERS reports

441

244 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. EOVIST is not approved for intrathecal use [see Warnings and Precautions (5.1) ]. Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of EOVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or Acute kidney injury. Screen...

What it is approved for

From the label in effect Mar 2, 2026.

EOVIST is indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. EOVIST is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. ( 1 )

Mechanism: Gadoxetate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues. Gadoxetate is selectively taken up by hepatocytes, resulting in increased signal intensity in liver tissue.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • EOVIST · GADOXETATE DISODIUM 2.72145GM/15ML (181.43MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • EOVIST · GADOXETATE DISODIUM 1.8143GM/10ML (181.43MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gadoxetate Disodium" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash160
  • pain155
  • paraesthesia154
  • arthralgia153
  • burning sensation153
  • hypoaesthesia153
  • muscle spasms153
  • gadolinium deposition disease152
  • injury152
  • asthenia150
  • confusional state150
  • fatigue150

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20085
200916
201040
201147
201223
201319
201420
201514
201618
201714
201814
2019165
20207
20218
20225
202310
20248
20254
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Eovist (Gadoxetate Disodium) · HCPCS A9581

2024 spending

$1.3M

Beneficiaries

7,513

9,428 claims

Per beneficiary

$173

2024 ASP limit $14.74 per unit

View as table
YearSpending
2020$998,812
2021$1,117,691
2022$1,152,165
2023$1,199,615
2024$1,301,496

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 26 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.